LMWH in IVF - Biomarkers and benefits.

[1]  H. Klein,et al.  Lessons From the EThIGII Trial , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[2]  Catherine Harvey,et al.  Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. , 2016, The New England journal of medicine.

[3]  I. Greer,et al.  Corrigendum to “Precision Medicine in Assisted Conception: A Multicenter Observational Treatment Cohort Study of the Annexin A5 M2 Haplotype as a Biomarker for Antithrombotic Treatment to Improve Pregnancy Outcome” [EBioMedicine 10 (2016) 299-305] , 2016, EBioMedicine.

[4]  G D Adamson,et al.  International Committee for Monitoring Assisted Reproductive Technologies world report: Assisted Reproductive Technology 2008, 2009 and 2010. , 2016, Human reproduction.

[5]  P. Stanier,et al.  Investigation of the Annexin A5 M2 haplotype in 500 white European couples who have experienced recurrent spontaneous abortion. , 2015, Reproductive biomedicine online.

[6]  L. Rienzi,et al.  Reduction of multiple pregnancies in the advanced maternal age population after implementation of an elective single embryo transfer policy coupled with enhanced embryo selection: pre- and post-intervention study , 2015, Human reproduction.

[7]  P. Nihoyannopoulos,et al.  Preeclampsia: What Does the Father Have to Do with It? , 2015, Current Hypertension Reports.

[8]  J. Gris.  Is There Any Future for Low-Molecular-Weight Heparin in the Prevention of Pregnancy Loss? , 2015, Annals of Internal Medicine.

[9]  S. Degrelle,et al.  Review: Annexin-A5 and cell membrane repair. , 2015, Placenta.

[10]  P. Wieacker,et al.  M2/ANXA5 haplotype as a predisposition factor in Malay women and couples experiencing recurrent spontaneous abortion: a pilot study. , 2015, Reproductive biomedicine online.

[11]  N. Raine-Fenning,et al.  Heparin for assisted reproduction: summary of a Cochrane review. , 2015, Fertility and sterility.

[12]  J. Gris,et al.  Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? , 2014, British journal of haematology.

[13]  Osamu Ishihara,et al.  International Committee for Monitoring Assisted Reproductive Technologies world report: Assisted Reproductive Technology 2006. , 2013, Human reproduction.

[14]  H. Kurahashi,et al.  Contribution of fetal ANXA5 gene promoter polymorphisms to the onset of pre-eclampsia. , 2013, Placenta.

[15]  P. Wieacker,et al.  Further insights into the role of the annexin A5 M2 haplotype as recurrent pregnancy loss factor, assessing timing of miscarriage and partner risk. , 2013, Fertility and sterility.

[16]  D. Clark.  Aspirin and heparin to improve live birth rate in IVF for unexplained implantation failure? , 2013, Reproductive biomedicine online.

[17]  N. Raine-Fenning,et al.  Aspirin and heparin as adjuvants during IVF do not improve live birth rates in unexplained implantation failure. , 2013, Reproductive biomedicine online.

[18]  S. Sunkara,et al.  Effect of heparin on the outcome of IVF treatment: a systematic review and meta-analysis. , 2012, Reproductive biomedicine online.

[19]  T. Yonezawa,et al.  Loss of Maternal Annexin A5 Increases the Likelihood of Placental Platelet Thrombosis and Foetal Loss , 2012, Scientific Reports.

[20]  G. Tiscia,et al.  The M2 haplotype in the ANXA5 gene is an independent risk factor for idiopathic small-for-gestational age newborns. , 2012, Molecular human reproduction.

[21]  C. Laskin,et al.  Idiopathic recurrent miscarriage is caused mostly by aneuploid embryos. , 2012, Fertility and sterility.

[22]  C. Thaler,et al.  Paternal and maternal carriage of the annexin A5 M2 haplotype are equal risk factors for recurrent pregnancy loss: a pilot study. , 2012, Fertility and sterility.

[23]  H. Kurahashi,et al.  Polymorphisms in the annexin A5 gene promoter in Japanese women with recurrent pregnancy loss. , 2011, Molecular human reproduction.

[24]  B. Gallois,et al.  Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair , 2011, Nature communications.

[25]  E. Grandone,et al.  Reduced allele specific annexin A5 mRNA levels in placentas carrying the M2/ANXA5 allele. , 2010, Placenta.

[26]  J. Rand,et al.  The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis , 2010, Lupus.

[27]  G. Tiscia,et al.  Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications , 2009, Thrombosis and Haemostasis.

[28]  G. Tiscia,et al.  Annexin V expression in human placenta is influenced by the carriership of the common haplotype M2. , 2009, Fertility and Sterility.

[29]  G. Burton,et al.  Syncytial knots, sprouts, apoptosis, and trophoblast deportation from the human placenta. , 2009, Taiwanese journal of obstetrics & gynecology.

[30]  S. Nelson,et al.  The potential role of heparin in assisted conception. , 2008, Human reproduction update.

[31]  C. Reutelingsperger,et al.  Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. , 2008, Biochimica et biophysica acta.

[32]  M. Krawczak,et al.  A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. , 2007, Human molecular genetics.

[33]  J. Craig,et al.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. , 2005, The Cochrane database of systematic reviews.

[34]  A. Guha,et al.  Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. , 1994, American journal of obstetrics and gynecology.